Overview

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Octreotide